Induction of Labour Methods and Considerations

Cervical Assessment and Induction Methods

• The European Society of Cardiology recommends assessing the Bishop score to determine cervical favourability before selecting an induction method, with a favourable Bishop score indicating readiness for oxytocin and membrane rupture, while an unfavourable cervix requires cervical ripening first 1
• For labour induction with a favourable cervix, use oxytocin with artificial rupture of membranes; for an unfavourable cervix, use oral misoprostol solution 20-25 µg every 2-6 hours as the preferred pharmacological method, or mechanical methods in high-risk cardiac or cyanotic patients 1, 2

Primary Induction Methods

• The American College of Obstetricians and Gynecologists advises using oxytocin infusion with artificial rupture of membranes as the standard approach when the cervix is favourable 1
• For unfavourable cervix, the preferred pharmacological method is oral misoprostol solution 20-25 µg every 2-6 hours, which results in fewer cesarean sections and lower uterine hyperstimulation rates compared to higher doses 2
• Mechanical methods, such as Foley catheter, are preferable to pharmacological agents in patients with cyanosis, active cardiovascular disease, or conditions where drops in systemic vascular resistance or blood pressure would be detrimental 1

Critical Contraindications and Safety Considerations

• Misoprostol is absolutely contraindicated in women with previous cesarean delivery due to 13% uterine rupture risk, substantially higher than oxytocin (1.1%) or prostaglandin E2 (2%) 2, 3
• Dinoprostone is contraindicated in active cardiovascular disease due to profound blood pressure effects 1
• The American College of Obstetricians and Gynecologists advises avoiding misoprostol entirely in women with prior cesarean delivery 2

Special Population Considerations

• In women with advanced liver failure, misoprostol may be less suitable as it requires hepatic metabolism to convert from E1 to active E2 prostaglandin; consider alternative methods 2
• In cardiac patients or those with cyanosis, mechanical methods are preferred over prostaglandins to avoid systemic vascular resistance drops 1
• Prostaglandin E2 carries theoretical risk of coronary vasospasm and low risk of arrhythmias 1

Uterine Rupture Risk Stratification

• Oxytocin in prior cesarean: 1.1% rupture risk 3
• Prostaglandin E2 in prior cesarean: 2% rupture risk 1
• Misoprostol in prior cesarean: 13% rupture risk 2

Monitoring Requirements

• Continuous fetal heart rate and uterine activity monitoring is mandatory during all pharmacological induction methods 2

Common Pitfalls to Avoid

• Avoid prolonged induction time when cervix is unfavourable - consider mechanical methods or cesarean delivery if cervical ripening fails 1
• Do not use misoprostol in women with prior cesarean - the rupture risk is unacceptably high 2
• Avoid dinoprostone in active cardiovascular disease due to blood pressure effects 1

Adjunctive Considerations

• Prostaglandin E2 for induction or oxytocin for augmentation has not been associated with worsening lung function or asthma exacerbation, according to the European Respiratory Society 4
• Early epidural analgesia is preferred for pain relief and can be extended for emergency cesarean if needed, as recommended by the European Respiratory Society 4
• Active management of third stage with oxytocin is preferred over ergotamine (which may cause bronchospasm), as suggested by the European Respiratory Society 4

Misoprostol for Labor Induction – Evidence‑Based Guidelines

Indications & Recommended Dosing

• Low‑dose vaginal misoprostol (25 µg every 3–6 hours) is the standard regimen for cervical ripening and induction in term pregnancies with an unfavorable cervix; this approach is endorsed by ACOG and confirmed by multiple randomized trials. 5
• Higher‑dose regimens (50 µg every 6 hours) may be considered only in select cases, but they carry a markedly increased risk of uterine hyperstimulation and should be used with caution. 6
• Although the optimal interval between doses remains somewhat uncertain, evidence consistently shows that lower doses are both safer and effective for induction. 5

Efficacy & Cost Advantages

• Misoprostol is substantially less expensive than dinoprostone, costing approximately $0.36–$1.20 per 100 µg tablet versus $65–$75 for dinoprostone gel or $165 for the insert. 6

Absolute Contraindications & Safety Level

• Prior cesarean delivery or any uterine surgery constitutes an absolute contraindication because the uterine rupture risk rises to about 13 % (compared with ~1 % for oxytocin and ~2 % for prostaglandin E₂). This is a Level B recommendation from ACOG based on clear evidence. 5

Monitoring Requirements

• Continuous fetal heart‑rate and uterine‑activity monitoring must be instituted from 30 minutes to 2 hours after each misoprostol dose and maintained throughout labor to promptly detect uterine tachysystole (>5 contractions/10 min) and hyperstimulation (tachysystole with adverse fetal heart‑rate changes). 6

Safety Profile & Complication Rates

• Uterine tachysystole occurs less frequently with the 25 µg dose, showing rates comparable to those seen with dinoprostone. 5
• Misoprostol remains stable at room temperature and does not require refrigeration, unlike dinoprostone, which must be stored cold to preserve potency. This stability enhances accessibility, especially in resource‑limited settings. 6

Practical Implementation Algorithm (Evidence‑Based Steps)

All statements are derived from cited evidence (5, 6) and reflect current ACOG recommendations.

Contraindications and Safety of Dinoprostone for Cervical Ripening

Absolute Contraindications

• Active cardiovascular disease (including cyanotic heart disease, obstructive valve lesions, and pulmonary hypertension) is an absolute contraindication to dinoprostone because the drug can cause profound blood‑pressure reductions, carries a theoretical risk of coronary vasospasm, and has a low but real risk of arrhythmias. 7
• Prior cesarean delivery confers a ~2 % risk of uterine rupture when dinoprostone is used for cervical ripening, which is higher than the ~1.1 % rupture risk with oxytocin alone and markedly lower than the ~13 % rupture risk observed with misoprostol. 8

Relative Contraindications / Preferred Alternatives

• In women with any cardiovascular compromise (including cyanosis where a drop in systemic vascular resistance would be detrimental), mechanical cervical ripening (e.g., Foley catheter) is strongly preferred over dinoprostone. 7
• For patients seeking a vaginal birth after cesarean (VBAC), mechanical methods are the preferred approach; if a prostaglandin must be used, dinoprostone carries a 2 % rupture risk versus a 13 % risk with misoprostol. 8

Hemodynamic Effects of Prostaglandin E₂

• Prostaglandin E₂ (dinoprostone) produces more severe hemodynamic changes than prostaglandin E₁, including greater reductions in systemic vascular resistance and arterial blood pressure. [7][9]

Clinical Decision Guidance

• Screening step: When the Bishop score is < 6, first assess for absolute contraindications—active cardiovascular disease or severe pulmonary hypertension. 7
• If cardiovascular disease is present: Use only mechanical cervical ripening methods; dinoprostone should not be administered. 7
• If prior cesarean delivery: Prefer mechanical methods; if dinoprostone is considered, counsel that the uterine rupture risk is ≈ 2 % (vs ≈ 13 % with misoprostol). 8
• If no contraindications: Dinoprostone vaginal insert (10 mg) may be used for a maximum of 12 hours; beyond this duration the risk of uterine hyperstimulation rises and repeat dosing is discouraged. 7
• If cervical ripening fails after adequate exposure: Transition to mechanical methods or proceed to cesarean delivery rather than repeating dinoprostone. 7

Practical Safety Recommendations

• Never use dinoprostone in active cardiovascular disease because the associated blood‑pressure effects and arrhythmia risk are unacceptable. 7
• Avoid outpatient use of dinoprostone in high‑risk patients (those with cardiovascular disease or prior cesarean) – such patients should be managed in a tertiary center with multidisciplinary support. 7